以扩大盆腔淋巴结清扫组织病理学为参考评估氟-18前列腺特异性膜抗原1007正电子发射断层/计算机断层在新诊断中高危前列腺癌淋巴结分期中的价值
MINT试验前瞻性纳入99例新诊断中高危前列腺癌患者,以扩大盆腔淋巴结清扫组织病理学为参考评估18F-PSMA-1007 PET/CT淋巴结转移诊断准确性。患者水平灵敏度53.3%、特异度89.9%、阳性预测值69.6%、阴性预测值81.6%,30.3%患者组织学证实淋巴结转移。结论为特异度高但灵敏度中至低,不能替代扩大盆腔淋巴结清扫用于分期。
要点
- 患者水平灵敏度53.3%、特异度89.9%,18F-PSMA-1007 PET/CT检出淋巴结转移灵敏度中至低。
- 30.3%患者经组织学证实淋巴结转移,中位切除淋巴结数22枚(IQR 17-28)。
- 作者认为18F-PSMA-1007 PET/CT不能替代扩大盆腔淋巴结清扫用于分期。
核心结论
- 18F-PSMA-1007 PET/CT在中高危前列腺癌淋巴结转移检测中显示高特异度但中至低灵敏度,不能替代扩大盆腔淋巴结清扫用于分期。
- 作者认为需要进一步研究以确定其在初诊中高危前列腺癌淋巴结分期中的确切扫描指征。
研究设计与样本
- MINT试验前瞻性纳入新确诊中高危前列腺癌男性,行18F-PSMA-1007 PET/CT并由两名核医学医师阅片,以模板切除组织病理学为参考计算诊断准确性。
- 共评估99例男性,中位切除淋巴结数22枚(IQR 17-28)。
主要发现
- 99例中30.3%经组织学证实淋巴结转移。
- 患者水平灵敏度53.3%(95% CI 34.3-71.7%)、特异度89.9%(95% CI 80.2-95.8%)、阳性预测值69.6%(95% CI 51.2-83.3%)、阴性预测值81.6%(95% CI 75.0-86.8%)。
- 模板水平灵敏度12.9%(95% CI 5.7-23.9%)、特异度97.7%(95% CI 96.6-98.5%)、阳性预测值23.5%(95% CI 12.7-39.5%)、阴性预测值95.3%(95% CI 94.9-95.7%)。
关键数值与推荐
- 患者水平诊断准确性:灵敏度53.3%(95% CI 34.3-71.7%),特异度89.9%(95% CI 80.2-95.8%),阳性预测值69.6%(95% CI 51.2-83.3%),阴性预测值81.6%(95% CI 75.0-86.8%)。
- 模板水平诊断准确性:灵敏度12.9%(95% CI 5.7-23.9%),特异度97.7%(95% CI 96.6-98.5%),阳性预测值23.5%(95% CI 12.7-39.5%),阴性预测值95.3%(95% CI 94.9-95.7%)。
临床怎么用
- 作者结论指出18F-PSMA-1007 PET/CT不能替代扩大盆腔淋巴结清扫用于中高危前列腺癌淋巴结分期。
局限性
- 作者结论指出需要额外研究以确定其在初诊中高危前列腺癌淋巴结分期诊断路径中的确切扫描指征。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Fluorine-18 (18F) prostate-specific membrane antigen (PSMA) 1007 (18F-PSMA-1007) is a radiotracer used in prostate cancer (PCa) staging. So far, no large histopathological validation study has been conducted. The objective was to determine diagnostic accuracy of 18F-PSMA-1007 PET/CT compared to histopathological results of extended pelvic lymph node dissection (ePLND) in men with intermediate- or high-risk PCa. METHODS: Men with newly confirmed intermediate- or high-risk PCa were prospectively enrolled in the Molecular Imaging 18F-PSMA-1007 PET/CT for lymph Node sTaging in primary PCa (MINT) trial. PET/CT images were read by two nuclear medicine physicians. Diagnostic accuracy was evaluated by histopathology of template resections. Sensitivity, specificity, and positive and negative predictive values (PPV, NPV) for LNI detection of 18F-PSMA-1007 PET/CT were calculated. RESULTS: Ninety-nine men were evaluated; 30.3% showed histologically confirmed LNI. Median number of resected nodes was 22 (IQR 17-28). Patient-based sensitivity, specificity, PPV, and NPV were 53.3% (95% CI 34.3-71.7%), 89.9% (95% CI 80.2-95.8%), 69.6% (95% CI 51.2-83.3%), and 81.6% (95% CI 75.0-86.8%), respectively. Template-based sensitivity was 12.9% (95% CI 5.7-23.9%), specificity 97.7% (95% CI 96.6-98.5%), PPV 23.5% (95% CI 12.7-39.5%), and NPV 95.3% (95% CI 94.9-95.7%). CONCLUSION: 18F-PSMA-1007 PET/CT showed high specificity but moderate to low sensitivity for LNI detection in intermediate- and high-risk PCa. It cannot replace ePLND for staging. Additional studies are needed to determine exact scan indications in lymph node staging for the primary diagnostic pathway in intermediate- or high-risk PCa. TRIAL REGISTRY: December 12, 2018, Netherlands Trial Registry, NTR7670 ( https://www.trialregister.nl/trial/7428 ).
引用
- Hermsen R, Wedick EBC, Vinken MJM, et al. Lymph node staging with fluorine-18 prostate specific membrane antigen 1007-positron emission tomography/computed tomography in newly diagnosed intermediate- to high-risk prostate cancer using histopathological evaluation of extended pelvic node dissection as reference. Eur J Nucl Med Mol Imaging. 2022. PMID: 35543733. doi:10.1007/s00259-022-05827-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。